Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Revenue (2019 - 2025)

Keros Therapeutics' Revenue history spans 6 years, with the latest figure at $577000.0 for Q4 2025.

  • For Q4 2025, Revenue rose 213.58% year-over-year to $577000.0; the TTM value through Dec 2025 reached $244.3 million, up 203644.17%, while the annual FY2025 figure was $244.1 million, N/A changed from the prior year.
  • Revenue reached $577000.0 in Q4 2025 per KROS's latest filing, down from $14.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $211.2 million in Q1 2025 to a low of -$508000.0 in Q4 2024.
  • Average Revenue over 5 years is $23.4 million, with a median of $482500.0 recorded in 2024.
  • Peak YoY movement for Revenue: surged 1800100.0% in 2022, then plummeted 455.24% in 2024.
  • A 5-year view of Revenue shows it stood at $17.9 million in 2021, then rose by 0.56% to $18.0 million in 2022, then plummeted by 99.21% to $143000.0 in 2023, then tumbled by 455.24% to -$508000.0 in 2024, then soared by 213.58% to $577000.0 in 2025.
  • Per Business Quant, the three most recent readings for KROS's Revenue are $577000.0 (Q4 2025), $14.3 million (Q3 2025), and $18.2 million (Q2 2025).